Abstract
Prefrontal D1 hypoactivity is implicated in the pathophysiology of schizophrenia, and might contribute to sensorimotor gating deficits in schizophrenia patients, based on evidence that D1 blockade in the medial prefrontal cortex (MPFC) reduces prepulse inhibition of startle (PPI) in animal models. PPI is disrupted by systemic and intra-MPFC infusion of the D1 antagonist, SCH23390. We investigated the role of the MPFC in the PPI-disruptive effects of systemic SCH23390 administration, and more generally, in the dopaminergic regulation of PPI. PPI was measured in rats after forebrain manipulations, including systemic administration of SCH23390, ibotenic acid lesions of the MPFC, and 6OHDA-induced dopamine (DA) depletion from MPFC or nucleus accumbens. Systemic SCH23390 disrupted PPI; these effects were not opposed by ibotenic acid lesions of the MPFC. PPI remained intact after MPFC DA depletion, but--as predicted by Bubser and Koch [M. Bubser, M. Koch, Prepulse inhibition of the acoustic startle response of rats is reduced by 6 hydroxydopamine lesions of the medial prefrontal cortex, Psychopharmacology 113 (1994) 487-492]--a reduction in PPI from pre- to post-surgery correlated significantly with MPFC DA loss. The effects of syste...Continue Reading
References
Jul 1, 1978·Psychophysiology·D BraffL Bali
Jan 1, 1980·Journal of Neurochemistry·C J PycockR W Kerwin
Dec 1, 1994·The European Journal of Neuroscience·M Koch, M Bubser
Jan 1, 1994·Psychopharmacology·M Bubser, M Koch
Nov 1, 1994·Naunyn-Schmiedeberg's Archives of Pharmacology·K WedzonyM Zazula
Nov 1, 1995·Psychopharmacology·N R SwerdlowM A Geyer
Dec 5, 2000·Behavioural Pharmacology·N R SwerdlowM A Geyer
Jul 24, 2001·Psychopharmacology·M J MillanD Cussac
Sep 11, 2001·Psychopharmacology·D L BraffN R Swerdlow
Feb 20, 2004·The International Journal of Neuropsychopharmacology·Anissa Abi-Dargham
Apr 29, 2004·Psychopharmacology·C W Stevenson, Alain Gratton
Jul 15, 2004·Annals of the New York Academy of Sciences·David A LewisSusan Erickson
Aug 10, 2004·Psychopharmacology·Neal R SwerdlowAmanda Platten
Sep 24, 2004·Progress in Neurobiology·Jeremy K Seamans, Charles R Yang
Sep 29, 2005·Pharmacology, Biochemistry, and Behavior·Neal R SwerdlowRichard L Saint Marie
Citations
Jun 21, 2007·Psychopharmacology·Stella G GiakoumakiPanos Bitsios
Dec 7, 2007·Psychopharmacology·Judith A SiuciakAshley N Martin
Jun 24, 2008·Psychopharmacology·Neal R SwerdlowDavid L Braff
Mar 12, 2009·Psychopharmacology·Urs Meyer, Joram Feldon
Aug 18, 2012·Psychopharmacology·Daria Peleg-RaibsteinBenjamin K Yee
Aug 4, 2009·Neurotoxicity Research·Małgorzata PietraszekLucyna Antkiewicz-Michaluk
Apr 29, 2008·BMC Neuroscience·Shoji Tanaka
Jun 15, 2010·PLoS Biology·Michael A SiutaAurelio Galli
Jul 2, 2010·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·David KapfhamerUlrike Heberlein
Sep 11, 2009·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Jonathan P FadokRichard D Palmiter
Sep 14, 2011·Journal of Visualized Experiments : JoVE·Bridget Valsamis, Susanne Schmid
Dec 24, 2013·Psychopharmacology·Jodi E GresackVictoria B Risbrough
Dec 8, 2009·Behavioural Brain Research·Osamu NakagawasaiTakeshi Tadano
Sep 22, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·R E FeatherstoneP J Fletcher
Dec 16, 2006·Physiology & Behavior·Jack C TurvinMary F Kritzer
Jan 15, 2009·Neuroscience·M I SchubertD P Auer
Apr 10, 2013·Pharmacology, Biochemistry, and Behavior·Neal R SwerdlowMichelle R Breier
Aug 30, 2008·The International Journal of Neuropsychopharmacology·Christine WinterUrs Meyer
May 19, 2009·Behavioural Brain Research·Daniela MohrMarkus Fendt
Nov 21, 2017·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neal R SwerdlowGregory A Light
May 28, 2017·Journal of Alzheimer's Disease : JAD·Alexandre V IvachtchenkoAndrey Ivashchenko
Feb 26, 2021·Developmental Psychobiology·Carly M DrzewieckiJanice M Juraska